

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

April 2013

Vol. 41, No. 4

CONTENTS

SHORT COMMUNICATIONS

Retrospective Analysis of P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier in Humans. *Hiroshi Sugimoto, Hideki Hirabayashi, Nobuyuki Amano, and Toshiya Moriwaki* **683**

□ Interleukins-12 and -23 Do Not Alter Expression or Activity of Multiple Cytochrome P450 Enzymes in Cryopreserved Human Hepatocytes. *Shannon Dallas, Sowvik Chattopadhyay, Carlo Sensenhauser, Ameesha Batheja, Monica Singer, and Jose Silva* **689**

The Relative Protein Abundance of UGT1A Alternative Splice Variants as a Key Determinant of Glucuronidation Activity In Vitro. *Mélanie Rouleau, Joannie Roberge, Sarah-Ann Falardeau, Lyne Villeneuve, and Chantal Guillemette* **694**

Reversible Inhibition of Human Carboxylesterases by Acyl Glucuronides. *Natalie R. Inoue, Adrian Hall, W. George Lai, and Eric T. Williams* **698**

Serum Levels of 25-Hydroxyvitamin D and the CYP3A Biomarker 4 β -Hydroxycholesterol in a High-Dose Vitamin D Supplementation Study. *Linda Björkhem-Bergman, Hanna Nylén, Anna-Carin Norlin, Jonatan D. Lindh, Lena Ekström, Erik Eliasson, Peter Bergman, and Ulf Diczfalussy* **704**

ARTICLES

□ Methadone N-Demethylation by the Common CYP2B6 Allelic Variant CYP2B6.6. *Sarah Gadel, Amanda Crafford, Karen Regina, and Evan D. Kharasch* **709**

□ Pharmacokinetics, Metabolism, and Excretion of the Glycogen Synthase Kinase-3 Inhibitor LY2090314 in Rats, Dogs, and Humans: A Case Study in Rapid Clearance by Extensive Metabolism with Low Circulating Metabolite Exposure. *Maciej J. Zamek-Gliszczyński, Trent L. Abraham, Jeffrey J. Alberts, Palaniappan*

Kulanthaivel, Kimberley A. Jackson, Kay H. Chow, Denis J. McCann, Haitao Hu, Shelby Anderson, Nathan A. Furr, Robert J. Barbuch, and Kenneth C. Cassidy **714**

Pharmacokinetic and Pharmacodynamic Modeling of Hedgehog Inhibitor TAK-441 for the Inhibition of Gli1 messenger RNA Expression and Antitumor Efficacy in Xenografted Tumor Model Mice. *Akifumi Kogame, Yoshihiko Tagawa, Sachio Shibata, Hideaki Tojo, Maki Miyamoto, Kimio Tohyama, Takahiro Kondo, Shimoga Prakash, Wen Chyi Shyu, and Satoru Asahi* **727**

Evaluation of Hepatic Disposition of Paroxetine Using Sandwich-Cultured Rat and Human Hepatocytes. *Norikazu Matsunaga, Ken-ichi Nunoya, Masahiro Okada, Mikio Ogawa, and Ikumi Tamai* **735**

□ Application of a Physiologically Based Pharmacokinetic Model to Assess Propofol Hepatic and Renal Glucuronidation in Isolation: Utility of In Vitro and In Vivo Data. *Katherine L. Gill, Michael Gertz, J. Brian Houston, and Aleksandra Galetin* **744**

Tariquidar and Elacridar Are Dose-Dependently Transported by P-Glycoprotein and Bcrp at the Blood-Brain Barrier: A Small-Animal Positron Emission Tomography and In Vitro Study. *Jens P. Bankstahl, Marion Bankstahl, Kerstin Römermann, Thomas Wanek, Johann Stanek, Albert D. Windhorst, Maren Fedrowitz, Thomas Erker, Markus Müller, Wolfgang Löscher, Oliver Langer, and Claudia Kuntner* **754**

□ Characterization of Four New Mouse Cytochrome P450 Enzymes of the CYP2J Subfamily. *Joan P. Graves, Matthew L. Edin, J. Alyce Bradbury, Artiom Gruzdev, Jennifer Cheng, Fred B. Lih, Tiwanda A. Masinde, Wei Qu, Natasha P. Clayton, James P. Morrison, Kenneth B. Tomer, and Darryl C. Zeldin* **763**

Continued on next page

Peginesatide Clearance, Distribution, Metabolism, and Excretion in Monkeys following Intravenous Administration. <i>Kathryn W. Woodburn, Kei-Lai Fong, Susan D. Wilson, Steven Sloneker, Paul Strzemienski, Eric Solon, Yuu Moriya, and Yoshihiko Tagawa.</i>	774	The Inactivation of Human CYP2E1 by Phenethyl Isothiocyanate, a Naturally Occurring Chemo-preventive Agent, and Its Oxidative Bioactivation. <i>Yasushi Yoshigae, Chitra Sridar, Ute M. Kent, and Paul F. Hollenberg</i>	858
☐ Identification of the Active Components in Shenmai Injection that Differentially Affect Cyp3a4-Mediated 1'-Hydroxylation and 4-Hydroxylation of Midazolam. <i>Caiwen Zeng, Fang He, Chunhua Xia, Hong Zhang, and Yuqing Xiong.</i>	785	Potential Role of <i>UGT1A4</i> Promoter SNPs in Anastrozole Pharmacogenomics. <i>Vineetha Koroth Edavana, Ishwori B. Dhakal, Suzanne Williams, Rosalind Penney, Gunnar Boysen, Aiwei Yao-Borengasser, and Susan Kadlubar.</i>	870
Organic Anion Transporter 3 Interacts Selectively with Lipophilic β -Lactam Antibiotics. <i>Aaron T. Wolman, Michael R. Gionfriddo, Gregory A. Heindel, Paran Mukhija, Sarah Witkowski, Ajay Bommarreddy, and Adam L. VanWert.</i>	791	☐ Absorption, Elimination, and Metabolism of CS-1036, a Novel α -Amylase Inhibitor in Rats and Monkeys, and the Relationship between Gastrointestinal Distribution and Suppression of Glucose Absorption. <i>Tomohiro Honda, Yoko Kaneno-Urasaki, Takahiro Murai, Masayo Kakuta, Hatsumi Nasu, Eiko Namba, Tetsufumi Koga, Akira Okuno, and Takashi Izumi.</i>	878
☐ A Physiologically Based Pharmacokinetic Model to Predict Disposition of CYP2D6 and CYP1A2 Metabolized Drugs in Pregnant Women. <i>Alice Ban Ke, Srikanth C. Nallani, Ping Zhao, Amin Rostami-Hodjegan, Nina Isoherranen, and Jashvant D. Unadkat</i>	801	Identification and Characterization of Novel Alternative Splice Variants of Human Constitutive Androstane Receptor in Liver Samples of Koreans and Caucasians. <i>Eun-Jung Choi, Yin-Jin Jang, Eun-Young Cha, Jae-Gook Shin, and Sang Seop Lee</i>	888
☐ Metabolites of PPI-2458, a Selective, Irreversible Inhibitor of Methionine Aminopeptidase-2: Structure Determination and In Vivo Activity. <i>Christopher C. Arico-Muendel, Bruce Belanger, Dennis Benjamin, Heather S. Blanchette, Teresa M. Caiazzo, Paolo A. Centrella, Jennifer DeLorey, Elisabeth G. Doyle, Ulrike Gradhand, Sarah T. Griffin, Susan Hill, Matthew T. Labenski, Barry A. Morgan, Gary O'Donovan, Kavirayani Prasad, Steven Skinner, Nazbeh Taghizadeh, Charles D. Thompson, James Wakefield, William Westlin, and Kerry F. White.</i>	814	Lysosomal Sequestration (Trapping) of Lipophilic Amine (Cationic Amphiphilic) Drugs in Immortalized Human Hepatocytes (Fa2N-4 Cells). <i>Faraz Kazmi, Tiffini Hensley, Chad Pope, Ryan S. Funk, Greg J. Loewen, David B. Buckley, and Andrew Parkinson.</i>	897
Characterization of Efflux Transporters Involved in Distribution and Disposition of Apixaban. <i>Donglu Zhang, Kan He, John J. Herbst, Janet Kolb, Wilson Shou, Lifei Wang, Praveen V. Balimane, Yong-Hae Han, Jinping Gan, Charles E. Frost, and W. Griffith Humphreys</i>	827	Investigating the Enteroenteric Recirculation of Apixaban, a Factor Xa Inhibitor: Administration of Activated Charcoal to Bile Duct-Cannulated Rats and Dogs Receiving an Intravenous Dose and Use of Drug Transporter Knockout Rats. <i>Donglu Zhang, Charles E. Frost, Kan He, A. David Rodrigues, Xiaoli Wang, Lifei Wang, Theunis C. Goosen, and W. Griffith Humphreys</i>	906
☐ Predicting Metabolic Clearance for Drugs That Are Actively Transported into Hepatocytes: Incubational Binding as a Consequence of in Vitro Hepatocyte Concentration Is a Key Factor. <i>Pär Nordell, Petter Svanberg, James Bird, and Ken Grime</i>	836	Transport of A_1 Adenosine Receptor Agonist Tecadenoson by Human and Mouse Nucleoside Transporters: Evidence for Blood-Brain Barrier Transport by Murine Equilibrative Nucleoside Transporter 1 mENT1. <i>Eve-Irene Lepist, Vijaya L. Damaraju, Jing Zhang, Wendy P. Gati, Sylvia Y.M. Yao, Kyla M. Smith, Edward Karpinski, James D. Young, Kwan H. Leung, and Carol E. Cass</i>	916
☐ RNA-Sequencing Quantification of Hepatic Ontogeny and Tissue Distribution of mRNAs of Phase II Enzymes in Mice. <i>Hong Lu, Sumedha Gunewardena, Julia Y. Cui, Byunggil Yoo, Xiao-bo Zhong, and Curtis D. Klaassen</i>	844		

ACCELERATED COMMUNICATION

- ☐ Drug Transporters on Arachnoid Barrier Cells Contribute to the Blood–Cerebrospinal Fluid Barrier. *Kazuto Yasuda, Cynthia Cline, Peter Vogel, Mihaela Onciu, Soghra Fatima, Brian P. Sorrentino, Ranjit K. Thirumaran, Sean Ekins, Yoshihiro Urade, Ko Fujimori, and Erin G. Schuetz* **923**

ERRATUM

- Correction to “Characterization of Human Cytochrome P450s Involved in the Bioactivation of Clozapine”. . . **932**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Representative sagittal PET summation images (0–60 minutes) of [11C]TQD for (A) scan 1 in wild-type (WT), Mdr1a/b(2/2), Bcrp1(2/2), and Mdr1a/b(2/2)Bcrp1(2/2) mice. The radiation scale is set from 0.0% to 10.0% injected dose per gram (%ID/g). (C) Mean (6 S.E.M.) whole-brain time-activity curves of all mice types (WT, black squares; Mdr1a/b(2/2), red circles; Bcrp1(2/2), green triangles Mdr1a/b(2/2)Bcrp1(2/2), blue diamonds; n = 5 per type) are shown. Unlabeled TQD (15 mg/kg) was administered as an intravenous bolus at 60 minutes after start of scan 1 (C). Application of cold TQD is indicated by an arrow. See article by Bankstahl et al. on page 754 of this issue.